Increased incidence of rheumatoid arthritis after COVID-19

[1]  M. Gershwin,et al.  Molecular mimicry and autoimmunity in the time of COVID-19 , 2023, Journal of Autoimmunity.

[2]  J. Ciaffi,et al.  Post-Acute COVID-19 Joint Pain and New Onset of Rheumatic Musculoskeletal Diseases: A Systematic Review , 2023, Diagnostics.

[3]  M. Mitreva,et al.  Poly(ADP-ribose) polymerase 9 mediates early protection against Mycobacterium tuberculosis infection by regulating type I IFN production , 2023, The Journal of clinical investigation.

[4]  J. Anaya,et al.  Post-COVID Syndrome in Adults—An Overview , 2023, Viruses.

[5]  C. Scheidt-Nave,et al.  Incident autoimmune diseases in association with a SARS-CoV-2 infection: A matched cohort study , 2023, medRxiv.

[6]  R. Chang,et al.  Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study , 2023, eClinicalMedicine.

[7]  Y. Chávez,et al.  Molecular mimicry among human proteinase 3 and bacterial antigens: implications for development of c-ANCA associated vasculitis , 2022, Oxford open immunology.

[8]  J. Anaya,et al.  Is post-COVID syndrome an autoimmune disease? , 2022, Expert review of clinical immunology.

[9]  Quanzhen Li,et al.  Autoimmunity is a hallmark of post-COVID syndrome , 2022, Journal of translational medicine.

[10]  J. Fernández-Niño,et al.  Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort , 2022, The Lancet Healthy Longevity.

[11]  A. Leone,et al.  Heat Shock Proteins Alterations in Rheumatoid Arthritis , 2022, International journal of molecular sciences.

[12]  G. Narasimhan,et al.  Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins , 2022, bioRxiv.

[13]  Oscar J. Espinosa,et al.  Characterization of the population affiliated to the subsidized health insurance scheme in Colombia: a systematic review and meta-analysis , 2022, International Journal for Equity in Health.

[14]  J. Anaya,et al.  Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome , 2022, The Journal of infectious diseases.

[15]  Mark S. Anderson,et al.  Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths , 2021, Science Immunology.

[16]  A. Jahangiri,et al.  SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage , 2021, Frontiers in Immunology.

[17]  J. Anaya,et al.  Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19 , 2021, Journal of Translational Autoimmunity.

[18]  Y. Shoenfeld,et al.  The SARS-CoV-2 as an instrumental trigger of autoimmunity , 2021, Autoimmunity Reviews.

[19]  A. Barabasi,et al.  PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation , 2016, Nature Communications.

[20]  A. R. Gani,et al.  The PARP family: insights into functional aspects of poly (ADP‐ribose) polymerase‐1 in cell growth and survival , 2016, Cell proliferation.

[21]  M. Kaplan,et al.  Poly‐ADP‐ribosyl polymerase‐14 promotes T helper 17 and follicular T helper development , 2015, Immunology.

[22]  M. Rosado,et al.  Beyond DNA repair, the immunological role of PARP‐1 and its siblings , 2013, Immunology.

[23]  Y. Shoenfeld,et al.  Infectious Aspects and the Etiopathogenesis of Rheumatoid Arthritis , 2010, Clinical reviews in allergy & immunology.

[24]  OUP accepted manuscript , 2022, Journal of Infectious Diseases.

[25]  D.,et al.  Regression Models and Life-Tables , 2022 .